An assessment of urethral radiation exposure in the treatment of endometrial and rectal cancers.


Journal

International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041

Informations de publication

Date de publication:
04 2023
Historique:
received: 10 06 2022
accepted: 03 09 2022
medline: 28 3 2023
pubmed: 2 10 2022
entrez: 1 10 2022
Statut: ppublish

Résumé

Female survivors of endometrial and rectal cancers have increased risk of urinary incontinence. Survivors with prior radiation therapy are counseled against mesh incontinence surgery. We hypothesize that urethral radiation dose varies based on modality which may influence surgical risks. We aimed to demonstrate urethral radiation dose differences between vaginal brachytherapy (VBT) and external beam radiation therapy (EBRT). This is a retrospective cohort study of women exposed to VBT for endometrial cancer and EBRT for rectal cancer. The urethra was contoured on CT imaging to calculate radiation doses in centigray (cGy). The primary outcome was the percent of treatment radiation dose estimated to be received by the urethra based on the volume dose to 0.2 cc of urethra. Secondary outcomes were point doses to the bladder neck, mid-urethra, and total mean urethral dose. Descriptive statistics described demographic characteristics. Bivariate analyses compared urethral radiation dose based on radiation modality. Between 2014-2017, 32 women treated were included: 18 with VBT and 14 with EBRT. Mean ± SD urethral volume doses were lower in VBT (1266 cGy ± 533, 42.2% of prescribed treatment dose) compared to EBRT (5051 cGy ± 192, 100.2% of prescribed treatment dose), p < 0.0001. VBT also had significantly lower mean total urethral dose and point doses to bladder neck and mid- urethra compared to EBRT (p < 0.0001). The female urethra is exposed to significantly less radiation in VBT compared to EBRT. These data highlight that modality of pelvic radiation should be considered in treatment counseling on urinary incontinence in women.

Identifiants

pubmed: 36181547
doi: 10.1007/s00192-022-05363-7
pii: 10.1007/s00192-022-05363-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

929-935

Subventions

Organisme : NCATS NIH HHS
ID : UL1TR001420
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR001420
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The International Urogynecological Association.

Références

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/10.3322/caac.21590 .
Erekson EA, Sung VW, DiSilvestro PA, Myers DL. Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(2):159–63. https://doi.org/10.1007/s00192-008-0755-z .
doi: 10.1007/s00192-008-0755-z pubmed: 18985266
Dobberfuhl AD. Evaluation and treatment of female stress urinary incontinence after pelvic radiotherapy. Neurourol Urodyn. 2019;38(Suppl 4):S59-s69. https://doi.org/10.1002/nau.23839 .
doi: 10.1002/nau.23839 pubmed: 30311659
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–23. https://doi.org/10.1016/s0140-6736(09)62163-2 .
doi: 10.1016/s0140-6736(09)62163-2 pubmed: 20206777
Yashar CM. Basic Principles in Gynecologic Radiotherapy In: DiSaia PJ (ed) Clinical Gynecologic Oncology. 9th edn. Elsevier; 2018. pp 586–605.
Rajagopalan MS, Kannan N, Kim H, Houser CJ, Beriwal S. Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. Brachytherapy. 2013;12(3):248–53. https://doi.org/10.1016/j.brachy.2012.10.005 .
doi: 10.1016/j.brachy.2012.10.005 pubmed: 23453679
Spampinato S, Tanderup K, Marinovskij E, Axelsen S, Pedersen EM, Pötter R, Lindegaard JC, Fokdal L. MRI-based contouring of functional sub-structures of the lower urinary tract in gynaecological radiotherapy. Radiother Oncol. 2020;145:117–24. https://doi.org/10.1016/j.radonc.2019.12.011 .
doi: 10.1016/j.radonc.2019.12.011 pubmed: 31931290
Spampinato S, Fokdal L, Marinovskij E, Axelsen S, Pedersen EM, Pötter R, Lindegaard JC, Tanderup K. Assessment of dose to functional sub-structures in the lower urinary tract in locally advanced cervical cancer radiotherapy. Phys Med. 2019;59:127–32. https://doi.org/10.1016/j.ejmp.2019.01.017 .
doi: 10.1016/j.ejmp.2019.01.017 pubmed: 30772142
Amsbaugh MJ, Bhatt N, Hunter T, Gaskins J, Parker L, Metzinger D, Amsbaugh A, Sowards K, El-Ghamry M. Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer. Brachytherapy. 2015;14(5):600–5. https://doi.org/10.1016/j.brachy.2015.05.007 .
doi: 10.1016/j.brachy.2015.05.007 pubmed: 26087868
Thibault I, Lavallée MC, Aubin S, Laflamme N, Vigneault E. Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: clinical outcomes and dose–volume histogram analysis. Brachytherapy. 2012;11(3):181–91. https://doi.org/10.1016/j.brachy.2011.06.005 .
doi: 10.1016/j.brachy.2011.06.005 pubmed: 21862418
Withers HR, Thames HD Jr, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1(2):187–91. https://doi.org/10.1016/s0167-8140(83)80021-8 .
doi: 10.1016/s0167-8140(83)80021-8 pubmed: 6680223
Hoffmann AL, Nahum AE. Fractionation in normal tissues: the (α/β)eff concept can account for dose heterogeneity and volume effects. Phys Med Biol. 2013;58(19):6897–914. https://doi.org/10.1088/0031-9155/58/19/6897 .
doi: 10.1088/0031-9155/58/19/6897 pubmed: 24029492
Tewari KS, Monk BJ. Invasive Cervical Cancer. In: DiSaia PJ, Creasman WT (eds) Clinical Gynecologic Oncology 9edn. Elsevier, Inc.; 2018. pp 38–104.
Amsbaugh MJ, Bhatt N, Hunter T, Gaskins J, Parker L, Metzinger D, Amsbaugh A, Sowards K, El-Ghamry MN. Computed tomography-planned interstitial brachytherapy for locally advanced gynecologic cancer: Outcomes and dosimetric predictors of urinary toxicity. Brachytherapy. 2016;15(1):49–56. https://doi.org/10.1016/j.brachy.2015.10.001 .
doi: 10.1016/j.brachy.2015.10.001 pubmed: 26614237
Shisler R, Sinnott JA, Wang V, Hebert C, Salani R, Felix AS. Life after endometrial cancer: A systematic review of patient-reported outcomes. Gynecol Oncol. 2018;148(2):403–13. https://doi.org/10.1016/j.ygyno.2017.11.007 .
doi: 10.1016/j.ygyno.2017.11.007 pubmed: 29150143
Bregendahl S, Emmertsen KJ, Lindegaard JC, Laurberg S. Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis. 2015;17(1):26–37. https://doi.org/10.1111/codi.12758 .
doi: 10.1111/codi.12758 pubmed: 25156386
Chen KS, Glaser SM, Kim H, Beriwal S. Differences in urethral dosimetry between CT and MR imaging in multichannel vaginal cylinder brachytherapy. Brachytherapy. 2017;16(5):964–7. https://doi.org/10.1016/j.brachy.2017.06.002 .
doi: 10.1016/j.brachy.2017.06.002 pubmed: 28694115

Auteurs

Katherine Hines (K)

Wake Forest Department of Urology, Division of Female Pelvic Health, Winston-Salem, NC, USA.

Karina Nieto (K)

Wake Forest Department of Radiation Oncology, Winston-Salem, NC, USA.

William Dezarn (W)

Wake Forest Department of Radiation Oncology, Winston-Salem, NC, USA.

Kathryn Greven (K)

Wake Forest Department of Radiation Oncology, Winston-Salem, NC, USA.

Bridget Krol (B)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Catherine Matthews (C)

Wake Forest Department of Urology, Division of Female Pelvic Health, Winston-Salem, NC, USA.

Candace Parker-Autry (C)

Wake Forest Department of Urology, Division of Female Pelvic Health, Winston-Salem, NC, USA. cparkera@wakehealth.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH